World Health Organization Raises Warning Over Acute Shortage of Obesity Jabs
Less than a tenth of patients eligible to benefit from obesity jabs such as Wegovy have access to them, caution the World Health Organization as it releases its inaugural guidance on the medications.
Given more than one billion individuals worldwide currently living with obesity, it is urging increased and just access to GLP-1 medication.
According to forecasts, over two billion are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a chronic disease that can be addressed with thorough and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are significant barriers to broad access to the jabs that can assist patients in reducing significant body mass, explains the body.
Skinny Jab Shortage
Despite the current most favorable outlook, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – under 10% of those who need them, as stated by the health organization.
The guideline calls on governments and firms to expand access, by strategies including voluntary licensing.
The intellectual property rights on semaglutide – the primary component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
How Weight-Loss Drugs Function
GLP-1 drugs mimick a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so people reduce food intake.
Individuals usually see weight reduction within a few weeks of beginning the once-weekly jabs.
Evidence suggests users may see weight return a year later of stopping the drug, because their usual appetite return.
To be overweight or obese elevates your chance for developing health problems, like diabetes, heart disease, brain attack, and certain malignancies.
Excess weight impacts individuals in all nations and was linked to millions of deaths worldwide in 2024, according to the health agency.
